UNSPSC 51102838: Clioquinol/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102838 Clioquinol/hydrocortisone is a Commodity code that in practice captures state and local pharmaceutical procurement across a broader range of medications and health-related products than the code's nominal name suggests. Recent state and local opportunities tagged under this code show purchasing of naloxone, drug deactivation systems, and other pharmaceutical supplies for community health and emergency response programs. State health departments and county public health agencies are the primary issuing bodies, sourcing through both direct procurement and cooperative purchasing vehicles such as MMCAP Infuse consortiums that allow multiple jurisdictions to leverage volume discounts on pharmaceutical warehouse orders.

Recent activity centers on Florida and Illinois. The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for doxycycline hyclate and ciprofloxacin hydrochloride tablets totaling $2.99 million over three years under an Invitation for Bid process. Seminole County, Florida posted an IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, requiring vendors to include shipping costs and maintain drug-free workplace and E-Verify compliance. The code shows limited recent activity overall; opportunities that do appear tend to involve established suppliers, volume-based pricing, and compliance-heavy procurement processes with federal funding implications.